2021
DOI: 10.1016/j.beem.2021.101578
|View full text |Cite
|
Sign up to set email alerts
|

Menopausal hormone therapy in women with medical conditions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
11
0
4

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 19 publications
(15 citation statements)
references
References 99 publications
0
11
0
4
Order By: Relevance
“…Low-dose transdermal HT is not associated with thrombotic risk in observational studies, and off-label use may be considered in women with significant VMS and a history of VTE if appropriately anticoagulated. 11,40,42,[82][83][84] For women with systemic lupus erythematosus and high disease activity, positive anticardiolipin antibody or positive lupus anticoagulant, oral HT should generally be avoided. On the other hand, HT may be prescribed to women with systemic lupus erythematosus who have mild to moderate disease activity who do not have additional risk factors for VTE.…”
Section: Vte and Pulmonary Embolismmentioning
confidence: 99%
“…Low-dose transdermal HT is not associated with thrombotic risk in observational studies, and off-label use may be considered in women with significant VMS and a history of VTE if appropriately anticoagulated. 11,40,42,[82][83][84] For women with systemic lupus erythematosus and high disease activity, positive anticardiolipin antibody or positive lupus anticoagulant, oral HT should generally be avoided. On the other hand, HT may be prescribed to women with systemic lupus erythematosus who have mild to moderate disease activity who do not have additional risk factors for VTE.…”
Section: Vte and Pulmonary Embolismmentioning
confidence: 99%
“…Important risks to counsel patients on when starting HT include the low risk of stroke and venous thromboembolism (VTE) when using oral formulations. 26…”
Section: Additional Ht Benefitsmentioning
confidence: 99%
“…25 When considering formulation of HT, micronized progesterone, dydrogesterone, and drospirenone seem to be most neutral and possibly even beneficial on blood pressure compared with synthetic progestins. 26 Oral estrogen is associated with increased vasoconstriction and/ or increased sodium retention with resultant…”
Section: For Women With Hypertension Prescribe Transdermal Htmentioning
confidence: 99%
See 1 more Smart Citation
“…Menopause hormone therapy (MHT), currently available in an ever-expanding array of formulations, routes of administration, and dosages, continues to appear to be the most effective treatment for menopause-related symptoms. However, the decision to implement it may be complex, especially in women with chronic medical conditions, such as diabetes, obesity and autoimmune diseases [ 45 , 46 ]. An attempt to evaluate the effectiveness of MHT in relieving oral symptoms in postmenopausal women with dry mouth was undertaken in a recent study by Wang et al The study was conducted with the help of a questionnaire related to oral dryness and laboratory estimation of salivary estradiol levels in unstimulated saliva before and after case group was subjected to MHT.…”
Section: Saliva Of Menopausal Womenmentioning
confidence: 99%